Search for:
Category

Submenue

Category

At present, certain promotional activities (e.g., sweepstakes, raffle games or random premiums) are subject to the Gambling Act, B.E. 2478 (1935), which require the business operator to get permission from the Department of Provincial Administration. The Gambling Act regulates all sweepstakes activities with a strict and complicated permission system. The Office of the Council of State has now updated the requirements under the Gambling Act by passing the Bill on Sweepstakes Activities in the Course of Business or Occupation to reduce the strict procedures and difficulties for business operators in arranging these promotional activities.

To facilitate better traceability and follow-up actions in the event of safety or quality issues, the Health Science Authority (HSA) is launching a voluntary notification initiative for health supplements and traditional medicines. From 1 August 2022, companies may submit documents regarding their products to the HSA. If the products meet the necessary safety and quality standards and labelling requirements, they will be published on the HSA’s database, which patients and consumers can refer to when considering suitable health supplements and traditional medicines.

In 2021-2022, the digital assets industry in Thailand has been growing significantly as more big players in the traditional financial industry and start-up players enter into the digital assets market. It seems that the frenzy of price volatility and the regulatory complexities could not slow down the rise of crypto activities. To keep up with these dynamic and evolving regulatory developments in 2022, we have revised this publication to provide an update of the regulations pertaining to digital assets in Thailand, which cover the regulations regarding custodial wallet providers, digital asset payments and NFTs, including the SEC’s proposed rules on ready-to-use utility tokens, advertisements and IT standards.

In 2020, the European Commission began a review of the EU’s rules on blood, tissues and cells used for medical treatments and therapies. Now the Commission has published a draft legislative proposal to amend the rules. The proposal does not recommend a complete overhaul: the EU will not change its definitions of blood, tissue and cell products. Yet it does promise a significant update to the two Directives published in the early 2000s that continue to govern the use of BTC components in the EU. Most importantly, the proposed legislation would be packaged as a Regulation rather than a Directive, meaning it would have a direct effect in the Member States.

On 20 June 2022, HM Treasury issued much-anticipated details on the forthcoming UK buy-now-pay-later (BNPL) regulatory regime. The Treasury’s approach to regulatory controls for agreements is essentially the same position that it took in its October 2021 consultation – a proportionate approach applying some but not all of the consumer credit regulatory principles, with regulations tailored to apply to BNPL as a bespoke product.

On 15 June 2022 HM Treasury published the outcome to its consultation on amendments to the Money Laundering, Terrorist Financing and Transfer of Funds (Information on the Payer) Regulations 2017 (MLRs). The changes to the MLRs will be implemented through the Money Laundering and Terrorist Financing (Amendment) (No.2) Regulations 2022 Statutory Instrument. A draft of the Statutory Instrument and explanatory memorandum have also been published. The amendments bring the MLRs in line with updated FATF standards and fill gaps in the current operation of the UK’s AML regime, most significantly in relation to cryptoassets.

In November 2018, the law surrounding the prescription of medical cannabis was changed by the British Home Office. Promising developments occurred in the year after this, including the approval of a cannabis based drug for childhood epilepsy and the opening of London’s first medical cannabis clinic with 150 patients on a waiting list. Nevertheless, almost four years on from the relaxation of barriers to access, it appears that minimal tangible progress has been made, particularly as it pertains to patient access which was the key motivation triggering government officials such as Home Secretary Sajid Javid to change the law in 2018.